Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
09/30/2022
09/30/2021
09/30/2020
09/30/2014
09/30/2013
Revenus
0
0
0
0
0
0
Croissance des revenus (H/H)
--
--
--
--
--
--
Coût des ventes
0
0
0
0
--
--
Bénéfice brut
0
0
0
0
--
--
Vente, Général et Administration
0
0
0
0
0
0
Recherche et développement
--
--
--
--
--
--
Frais d'exploitation
0
0
0
0
0
0
Autres revenus (charges) non opérationnels
--
0
0
--
--
--
Bénéfice avant impôts
0
0
0
0
0
0
Charge d'impôt sur le revenu
0
--
--
0
0
0
Bénéfice net
0
0
0
0
0
0
Croissance du bénéfice net
--
--
--
--
--
--
Actions en circulation (diluées)
16.63
18.13
18.13
16.63
8.96
8.96
Variation des actions (H-H)
--
0%
9%
--
0%
0%
EPS (dilué)
0
0.02
0
0
0
0
Croissance du EPS
--
-4,800%
-86%
--
26%
-39%
Flux de trésorerie libre
0
0
0
0
0
0
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
0%
0%
0%
0%
--
--
Marge opérationnelle
0%
0%
0%
0%
0%
0%
Marge bénéficiaire
0%
0%
0%
0%
0%
0%
Marge du flux de trésorerie libre
0%
0%
0%
0%
0%
0%
EBITDA
0
0
0
0
0
0
Marge EBITDA
0%
0%
0%
0%
0%
0%
D&A pour le résultat opérationnel
0
0
0
0
0
0
EBIT
0
0
0
0
0
0
Marge EBIT
0%
0%
0%
0%
0%
0%
Taux d'imposition effectif
0%
--
--
0%
0%
0%
Follow-Up Questions
Quels sont les états financiers clés de THC Farmaceuticals Inc ?
Quels sont les ratios financiers clés pour CBDG ?
Comment les revenus de THC Farmaceuticals Inc sont-ils répartis par segment ou géographie ?
THC Farmaceuticals Inc est-elle rentable ?
THC Farmaceuticals Inc a-t-elle des passifs ?
Combien d'actions en circulation THC Farmaceuticals Inc a-t-elle ?
Statistiques clés
Clôture préc.
$0.02
Prix d'ouverture
$0.02
Plage de la journée
$0.02 - $0.02
Plage de 52 semaines
$0.0033 - $0.1
Volume
100
Volume moyen
1.2K
BPA (TTM)
-0.00
Rendement en dividend
--
Capitalisation boursière
$362.6K
Qu’est-ce que CBDG ?
THC Farmaceuticals, Inc. engages in the research and development of cannabis pharmaceutical products. The company is headquartered in Scottsdale, Arizona and currently employs 2 full-time employees. The company went IPO on 2012-08-22. The firm specializes in the discovery, development, and commercialization of novel cannabinoid-based products in dental, ophthalmology and other medical disciplines. The company offers the combination of its proprietary developments with its clinicians and scientists to unlock the therapeutic properties of cannabis and its bioactive compounds. The firm owns clinical research center and cannabidiol (CBD) manufacturing facility in California. Its business plan includes conducting cannabinoids research and development in collaboration with cannabis research centers worldwide with the goal of developing novel and advanced therapeutic methods for the treatment of common medical conditions with cannabis-based therapies and to conduct pre-clinical investigations and randomized, placebo-controlled trials of CBD-based compounds and develop condition-specific medications. The company offers a network of micro vending kiosk systems.